|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/05/20 Sarepta Therapeutics, Inc. S-8 8/05/20 3:151K ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: S-8 Registration Statement - Securities for an HTML 56K
Employee Benefit Plan
2: EX-5.1 Opinion of Counsel re: Legality HTML 9K
3: EX-23.2 Consent of Expert or Counsel HTML 6K
EXHIBIT 5.1
PRUDENTIAL TOWER 800 BOYLSTON STREET 
Sarepta Therapeutics, Inc.
215 First Street, Suite 415
Cambridge, Massachusetts 02142
Ladies and Gentlemen:
This opinion letter is furnished to you in connection with the registration statement on Form S‑8 (the “Registration Statement”), filed by Sarepta Therapeutics, Inc., a Delaware corporation (the “Company”), on the date hereof, with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), for the registration of an aggregate of 4,800,000 shares of Common Stock, $0.0001 par value, of the Company (the “Shares”). The Shares are issuable under the Company’s 2014 Employment Commencement Incentive Plan, as amended, and the Company’s 2018 Equity Incentive Plan, as amended (each, a “Plan,” and collectively, the “Plans”).
We are familiar with the actions taken by the Company in connection with the adoption of the Plans. We have examined such certificates, documents and records and have made such investigation of fact and such examination of law as we have deemed appropriate in order to enable us to render the opinions set forth herein. In conducting such investigation, we have relied, without independent verification, upon certificates of officers of the Company, public officials and other appropriate persons.
The opinions expressed below are limited to the Delaware General Corporation Law.
Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized and, when the Shares have been issued and sold in accordance with the terms of the applicable Plan, the Shares will be validly issued, fully paid and nonassessable.
We hereby consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.
Very truly yours,
/s/ Ropes & Gray LLP
| This ‘S-8’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / Effective on: | 8/5/20 | 10-Q, 3, 4, 8-K | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 3/28/24 Sarepta Therapeutics, Inc. S-8 POS 3/28/24 4:220K Donnelley … Solutions/FA 8/02/23 Sarepta Therapeutics, Inc. S-8 8/02/23 4:69K Donnelley … Solutions/FA 8/02/22 Sarepta Therapeutics, Inc. S-8 8/02/22 4:58K Donnelley … Solutions/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/08/20 Sarepta Therapeutics, Inc. 8-K:5,9 6/04/20 12:237K ActiveDisclosure/FA 2/21/20 Sarepta Therapeutics, Inc. 8-K:5,9 2/19/20 11:170K ActiveDisclosure/FA 12/07/18 Sarepta Therapeutics, Inc. S-8 12/07/18 3:95K Donnelley … Solutions/FA 8/08/18 Sarepta Therapeutics, Inc. 10-Q 6/30/18 85:10M ActiveDisclosure/FA 6/28/17 Sarepta Therapeutics, Inc. 8-K:5,7,9 6/26/17 7:390K Donnelley … Solutions/FA 9/30/14 Sarepta Therapeutics, Inc. S-8 9/30/14 3:89K Donnelley … Solutions/FA 3/03/14 Sarepta Therapeutics, Inc. 10-K 12/31/13 86:8.8M Donnelley … Solutions/FA |